Aug. 17 at 8:10 PM
$MIST - Catheter ablation remains a highly effective and durable preventive therapy; however, it is not pursued by many eligible patients and does not address the need for acute, episodic symptom control. A safe effective self-administered therapy used outside the health care setting represents an important alternative for patients who are not ready to undergo ablation or who require interim symptom control while awaiting definitive therapy.
Although historical PiP strategies may be appropriate for select individuals, their use is constrained by outdated and limited evidence, off-label administration, and clinically relevant adverse effects, including hypotension and AV block. In this context, intranasal etripamil represents a promising advance, offering the potential for rapid, self-directed termination of PSVT episodes. If integrated thoughtfully into clinical practice, this approach may improve QoL, reduce reliance on emergency care, meaningfully expand patient options.
